Meet the Data: Conversations with Leading Experts on the Role of HCC and Immunotherapy
SIO Meet the Data Series: Explore the evolving landscape of hepatocellular carcinoma treatment in this four-part podcast series, featuring conversations with leading experts on the role of immunotherapy. This series features expert discussions highlighting emerging clinical trial evidence and addressing key knowledge gaps relevant to the implementation of these novel therapeutic regimens into clinical practice.

Episode 3: Exploring the Role of (Neo)Adjuvant Immunotherapy Pre-Transplant vs. Adjuvant Immunotherapy Post-Transplant

Should immunotherapy come before or after transplant? Experts Parissa Tabrizian and Beau Toskich explore one of the most critical questions in transplant oncology: when is the right time to introduce immunotherapy? Moderated by William Rilling, the discussion dives into the clinical evidence surrounding neoadjuvant and adjuvant immuno-oncology (IO) therapies in transplant settings.

Moderator:

• William Rilling, MD | Medical College of Wisconsin
Faculty:

• Beau Toskich, MD | Mayo Clinic
• Parissa Tabrizian, MD | Mount Sinai

Resources

Beau Toskich, MD

https://www.mayoclinic.org/biographies/toskich-beau-m-d/bio-20309020

Parissa Tabrizian, MD

https://profiles.mountsinai.org/parissa-tabrizian

Emerald-Y90 Trial:

https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4221

STORM Trial:

https://gut.bmj.com/content/68/6/1065

LEAP-012 Trial:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract

ImmunoXXL Trial:

https://clinicaltrials.gov/study/NCT05879328

IMbrave150 Trial:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2900800-6/fulltext

Disclaimer

This discussion is intended for healthcare professionals for educational purposes only. It does not constitute medical advice and should not replace individualized patient care decisions.